Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793953 | 0.95 | CYP2D6 (0.40) | ALDH1A1CYP2D6MAPTKDM4EGAA | |
| SCHEMBL2200994 | 0.90 | ALDH1A1 (0.38) | ALDH1A1MAPTKDM4EGAATLR4 | |
| SCHEMBL16391264 | 0.86 | HSD17B10 (0.40) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL2709751 | 0.81 | SLC6A3 (0.34) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL11896180 | 0.79 | TSHR (0.38) | ALDH1A1MAPTKDM4EGAATLR4 | |
| SCHEMBL16370559 | 0.76 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL5790092 | 0.75 | SMN1; SMN2 (0.37) | ALDH1A1KDM4ETLR4HPGDHSD17B10 | |
| SCHEMBL16503643 | 0.74 | CA1 (0.31) | ALDH1A1MAPTKMT2A | |
| SCHEMBL16327796 | 0.74 | ALDH1A1 (0.38) | ALDH1A1KDM4EHPGDHSD17B10PPM1B | |
| SCHEMBL13308097 | 0.72 | LMNA (0.39) | ALDH1A1MAPTKDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4237086-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3256450-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3368516-B1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | SHANGHAI JIA TAN PHARMATECH CO. LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| WO-2017075178-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075178-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-3159342-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-3159342-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016130818-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130818-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2015192761-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR | 辰欣药业股份有限公司 | 2015-12-23 | — | — | WO | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | ALDH1A1 1457/4885CYP2D6 2388/4885MAPT 4599/4885 |
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | MTOR, PIK3CA, PIK3CD | ALDH1A1 1561/4885CYP2D6 734/4885MAPT 3702/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | ALDH1A1 1221/4885CYP2D6 2084/4885MAPT 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.